Request for an Andexxa Value Analysis.

Request for an Andexxa Value Analysis. Ann Pharmacother. 2020 Jan 23;:1060028020902280 Authors: Yin E, McConnell KJ Abstract This perspective is a formal request to the American College of Cardiology and American Heart Association (ACC/AHA) to perform a value analysis on andexanet (Andexxa) similar to what was completed for the PCSK9 inhibitors in the 2018 ACC/AHA Blood Cholesterol guidelines. Based on the safety and efficacy concerns of andexanet alfa, a value statement in and or as an addendum to society guidelines is vital considering the high cost of therapy. In this era of ever-increasing health care costs, every clinician, health system, national society, insurer, and pharmaceutical company should work to be good stewards of our society's resources. PMID: 31971004 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31971004?dopt=Abstract

Source: The Annals of Pharmacotherapy - January 22, 2020 Category: Drugs & Pharmacology Authors: Yin E, McConnell KJ Tags: Ann Pharmacother Source Type: research